EE46 Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.300
https://www.valueinhealthjournal.com/article/S1098-3015(22)00501-0/fulltext
Section Title :
Section Order :
10260
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00501-0&doi=10.1016/j.jval.2022.04.300